Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2003
10/22/2003CN1125079C Cyclopeptolides
10/22/2003CN1125054C Novel imidazolidine derivatives, their preparation their use and pharmaceutical preparations comprising them
10/22/2003CN1125040C Therapeutic compound-fatty acid conjugates
10/22/2003CN1124843C Stable glassy state powder formulations
10/22/2003CA2424577A1 Use of huntingtin and related compounds for modulating cell survival
10/21/2003US6635752 Diagnosis of Aids
10/21/2003US6635748 Protein for use as antitumor agent; for use as antimetastsis agent
10/21/2003US6635746 Chlamydial vaccines and immunogenic compositions containing an outer membrane antigen and methods of preparation thereof
10/21/2003US6635744 Substantially pure fibroblast growth factor homologous factor-4 polypeptide having specified amino acid sequence; diagnosis and treatment of neurodegenerative and neoplastic disorders
10/21/2003US6635743 Isolated antibody or portion that binds to protein selected from those having specified amino acid sequences or fragments; control apoptosis for treatment of autoimmune disease, graft versus host disease, rheumatoid arthritis and lymphadenopathy
10/21/2003US6635742 Antibodies specific for semaphorin-like polypeptides
10/21/2003US6635740 Ligand/lytic peptide compositions and methods of use
10/21/2003US6635739 Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
10/21/2003US6635738 Oligopeptides, pieces of interleukin 1 beta converting enzyme, which successfully inhibit enzyme
10/21/2003US6635632 Alzheimer's disease
10/21/2003US6635627 Anti-cancer products for treating cystic fibrosis
10/21/2003US6635623 Early detection of cancer, metastatic cancer and/or arteriosclerosis
10/21/2003US6635621 Alpha amino acid amide derivatives; reducing cathepsins B, L, S and/or K activity
10/21/2003US6635620 Hydroxyproline derivatives
10/21/2003US6635619 Amino acid sequence 88, 96, 97, 98, 99 or 100; increasing serum and tissue levels of active component
10/21/2003US6635618 Glycopeptide phosphonate derivatives
10/21/2003US6635617 Minimizing toxic and mucose irritating phenols; improved bioavailability
10/21/2003US6635616 Laminin 15
10/21/2003US6635614 Use of lecithin-cholesterol acyltransferase (LCAT) to reduce accumulation of cholesterol
10/21/2003US6635483 Antisense polynucleotide targeted to a nucleic acid encoding the gene, thereby suppressing its expression; cDNA encapsulated in liposome; use as antitumor, anticarcinogenic or antiapoptotic; Alzheimer's disease
10/21/2003US6635482 Produced by hybridoma; cytokines; useful in diagnosis, prevention and treatment of immune system-related disorders
10/21/2003US6635480 Of given amino acid sequence; use in detecting and treating cell proliferation and immunological disorders by modulating its activity
10/21/2003US6635479 Hypothalamus-specific polypeptides
10/21/2003US6635477 Comprising a open reading frame; use in diagnosis, treatment and prevention
10/21/2003US6635473 Isolated nucleic acid encoding a fibrinogen-binding protein; useful in prevention, diagnosis and treatment of infections; can be administered to wounds or for coating prosthetics to inhibit binding of the bacteria
10/21/2003US6635466 Adenovirus serotype 30 (Ad30)
10/21/2003US6635462 Mutated form of arginine deiminase
10/21/2003US6635461 Encoded by isolated nucleic acid; has glycosyltransferase activity; given amino acid sequence; useful as diagnostic and therapeutic agent for cancer and thymus-related disorders
10/21/2003US6635450 Isolated P27 protein, nucleic acid molecules encoding same, methods of identifying agents acting on same, and uses of said agents
10/21/2003US6635447 Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
10/21/2003US6635445 Isolated DNA; given amino acid sequence; useful for diagnosis and management of ovarian diseases
10/21/2003US6635443 Isolated nucleic acid; given amino acid sequence; use in diagnosing and treating immune system-related disorders
10/21/2003US6635442 Encoded by isolated DNA molecule; given amino acid sequence; useful for studying effects of chemical agents on coupled adenylate cyclase and hormone-sensitive lipases; use in controlling obesity, diabetes and hyperlipidemia
10/21/2003US6635431 Recombinant lipolysis stimulated (LSR) comprising polypeptide of given sequence; use for selecting a compound for enhancing lipoprotein uptake in cells expressing the polypeptide
10/21/2003US6635424 Method for generating libraries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
10/21/2003US6635421 Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
10/21/2003US6635417 Complex formation between DSDNA and oligomer of cyclic heterocycles
10/21/2003US6635273 Methods of treating vascular diseases characterized by nitric oxide insufficiency
10/21/2003US6635268 Sustained delivery of an active agent using an implantable system
10/21/2003US6635258 Herpes simplex virus VP22 vaccines and methods of use
10/21/2003US6635256 Administering multiple domain glycoprotein hormones containing alpha subunit covalently linked to beta subunit to form single chain hormone and additional beta subunit noncovalently linked to tethered alpha subunit of single chain hormone
10/21/2003US6635255 CASB414:antigen overexpressed in several tumors
10/21/2003US6635252 Antibodies to superoxide dismutase-4
10/21/2003US6635251 Eotaxin-specific antibodies
10/21/2003US6635250 Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsus
10/21/2003US6635249 Methods for treating congestive heart failure
10/21/2003US6635248 Isolated polypeptide consisting of single chain of amino acids comprising one or more penetrating fragments from one or more penetrating antibodies, which penetrates into cell
10/21/2003US6635247 Administering neurotoxin
10/21/2003US6635244 Adenovirus E1B-55K single amino acid mutants and methods of use
10/21/2003US6635243 Drug including genetically engineered alpha, beta or gamma interferon, biocompatible polymer selected from group consisting of polyvinylpyrrolidone and polyethylene oxide, and biocompatible antioxidant, and having specified viscosity
10/21/2003US6635238 Also provided are methods for studying cell wall of oral bacterium, preventing spoilage of perishable items and a method for removing dextrans from surfaces utilized in sugar manufacture.
10/21/2003CA2294516C Ikk-.beta. proteins, nucleic acids and methods
10/21/2003CA2259123C Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
10/21/2003CA2182289C Immuno-stimulatory monoclonal antibodies
10/21/2003CA2157659C Use of porcine gal .alpha. (1,3) galactosyl transferase in xenograft therapies
10/21/2003CA2156825C Inhibition of intimal hyperplasia using antibodies to pdgf receptors
10/21/2003CA2138161C Glucagon-like peptide and insulinotropin derivatives
10/21/2003CA2132452C Casein kinase i-like protein kinase
10/21/2003CA2115049C Dna sequences encoding gelonin polypeptide
10/21/2003CA2076432C Humanized antibody derivatives that recognize difucosyl lewis blood group antigens y-6 and b-7-2
10/21/2003CA2072649C Methods and materials for expression of human plasminogen variant
10/21/2003CA2053924C Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics
10/21/2003CA2037884C Stabilized gonadotropin containing preparations
10/21/2003CA2017166C Metalloproteinase inhibitor
10/21/2003CA1341445C Improved t-pa lacking the first kringle domain
10/21/2003CA1341444C Modified tissue plasminogen activator
10/16/2003WO2003085966A1 Customized media interface
10/16/2003WO2003085400A1 Onset of force development as a marker of thrombin generation
10/16/2003WO2003085377A2 Novel pancortin-pablo protein interactions and methods of use thereof
10/16/2003WO2003085124A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/16/2003WO2003085110A2 Oligomeric compounds for the modulation hif-1alpha expression
10/16/2003WO2003085096A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/16/2003WO2003085090A2 A human ribonucleotide reductase m2 subunit
10/16/2003WO2003085085A2 Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
10/16/2003WO2003084996A2 Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
10/16/2003WO2003084995A2 Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
10/16/2003WO2003084993A1 Novel antagonists of mcp proteins
10/16/2003WO2003084990A1 Bage genes, proteins coded by the same, and their uses for the treatment or the diagnosis of melanomas
10/16/2003WO2003084987A2 Polypeptides from bacteria and uses thereof
10/16/2003WO2003084984A1 Heterocyclic amides with alpha-4 integrin antagonist activity
10/16/2003WO2003084980A2 Peptide amphiphile solutions and self assembled peptide nanofiber networks
10/16/2003WO2003084979A2 Novel peptides and the application thereof in therapy
10/16/2003WO2003084611A1 Depsipeptide for therapy of kidney cancer
10/16/2003WO2003084610A1 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
10/16/2003WO2003084567A1 Use of botulinum toxin for treating cardiovasular diseases
10/16/2003WO2003084566A2 Proteins involved in the regulation of energy homeostasis
10/16/2003WO2003084565A2 Ve-ptp as regulator of ve-cadherin mediated processes or disorders
10/16/2003WO2003084564A1 Insulin administration apparatus
10/16/2003WO2003084563A1 Glp-1 agonist and cardiovascular complications
10/16/2003WO2003084562A1 Chemokines mutants having improved oral bioavailability
10/16/2003WO2003084561A1 Use of long pentraxin ptx3 for the treatment of fgf-8 mediated tumour diseases
10/16/2003WO2003084560A2 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
10/16/2003WO2003084551A1 Agents for treating flaviviridae infections
10/16/2003WO2003084542A1 Neurotrophic factor production accelerator
10/16/2003WO2003084483A2 Methods for modulating angiogenesis via vegf
1 ... 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 ... 3163